Home » Archive

Marketwire

Marketwire, News, Syndication »

Ardea Biosciences Prices Public Offering of Common Stock

Posted by Mary Canady February 1st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Feb 1, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock, offered at a price to the public of $17.00 per share. The gros…

More...

Marketwire, News, Syndication »

Ardea Biosciences Announces Proposed Public Offering of Common Stock

Posted by Mary Canady January 31st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 31, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be…

More...

Marketwire, News, Syndication »

Medistem and ERCell Initiate Phase II RECOVER-ERC Heart Failure Trial

Posted by Mary Canady January 30th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 30, 2012) – Medistem Inc. (PINKSHEETS: MEDS) together with its Russian Licensee, ERCell LLC, announced successful dosing of 3 heart failure patients in the Non-Revascularizable IschEmic Cardiomyopathy treated with Re…

More...

Marketwire, News, Syndication »

Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA

Posted by Mary Canady January 30th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 30, 2012) – Cytori Therapeutics (NASDAQ: CYTX) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the ATHENA trial. ATHENA will investigate the use of the Celution┬« System, an…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source

Posted by Mary Canady January 26th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 26, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has temporarily suspended dosing patients in its PEDigree and Nexus trials. In these trials, iSONEPT is being test…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source

Posted by Mary Canady January 26th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 26, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has temporarily suspended dosing patients in its PEDigree and Nexus trials. In these trials, iSONEPT is being test…

More...

Marketwire, News, Syndication »

Ora Executives to Present at Allergy Drug Discovery & Development Conference in San Diego

Posted by Mary Canady January 26th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 26, 2012) – Leading allergy experts from Ora, Inc. will present at the GTC Bio Allergy Drug Discovery & Development Conference in San Diego. The meeting, taking place January 30-31st at the Paradise Point Resort & Sp…

More...

Marketwire, News, Syndication »

Dr. Alan Lewis, Previous CEO of Juvenile Diabetes Research Foundation, Joins Medistem Advisory Board

Posted by Mary Canady January 24th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 24, 2012) – Medistem Inc. (PINKSHEETS: MEDS) announced today appointment of Dr. Alan Lewis to the company’s advisory board. Dr. Lewis spent 15 years at the pharmaceutical company Wyeth-Ayerst, where he was Vice Presi…

More...

Marketwire, News, Syndication »

Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori’s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function

Posted by Mary Canady January 24th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 24, 2012) – Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO, the Company’s European clinical trial evaluating adipose-derived stem and regenera…

More...

Marketwire, News, Syndication »

Medistem and Licensee ERCell Receive Russian Regulatory Approval for the RECOVER-ERC Trial

Posted by Mary Canady January 23rd, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 23, 2012) – Medistem Inc. (PINKSHEETS: MEDS) together
with its Russian Licensee, ERCell LLC, have received approval to initiate
the first double-blind, placebo controlled universal donor stem cell trial
in Russian hi…

More...